
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments is in a strong position for long-term success due to the company's strong financial performance, focused strategy, and promising technology platform. The company's profitability targets for 2026 showcase its ability to successfully manage the expected cost trends for Medicare Advantage members, driven by the utilization of its proprietary software platform, Clover Assistant. With a majority of its members utilizing Clover Assistant-enabled physicians and strong retention rates, Clover is well-positioned to continue its growth and profitability in the coming years. While there are potential headwinds for 2027, including being paid as a 3.5-star plan and possible regulatory changes, management remains confident in the company's ability to effectively manage these challenges and maintain its profitability. With a strong base of returning members and a growing cohort, Clover shows potential for sustained profitability in the future.
Bears say
Clover Health Investments is facing several challenges that can negatively affect its financial performance and market position. The company's profitability is under pressure due to higher medical costs caused by increased utilization. Regulatory changes to the Medicare Advantage program could also impact the company's financial performance. Furthermore, the company has an unproven track record of sustained profitability in a highly competitive market. As a result, the stock may not be a profitable investment option in the long term.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares